Medical technology company Proteomics International Laboratories (ASX: PIQ) has announced a significant commercial development this morning with the news that its novel predictive diagnostics PromarkerD diabetes-detection test would be marketed and distributed in the United States.
The US is currently regarded as the largest market for diabetes in the world with over 30 million people (around 10% of the population) currently suffering from various types of diabetes.
Proteomics has agreed to a deal with Texas-based company PHDx, for the company to market its PromarkerD across the US under a national licence agreement.
Article: Proteomics’ predictive diabetes test to be sold in US and could soon be coming to Australia